Methylation markers for small cell lung cancer in peripheral blood leukocyte DNA

Journal of Thoracic Oncology

Volumn 5, Issue 6, 2010, Pages 778-785

  Wang, Liang ^a   Aakre, Jeremiah A ^a   Jiang, Ruoxiang ^a   Marks, Randolph S ^b   Wu, Yanhong ^a   Chen, Jun ^a,c   Thibodeau, Stephen N ^a   Pankratz, V Shane ^a   Yang, Ping ^c  

^a Department of Health Sciences Research   (United States)

^b Veterinary and Life Sciences   (United Kingdom)

^c CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; Leukocyte; Methylation; Small cell lung cancer

Indexed keywords

BIOLOGICAL MARKER; DNA; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN;

AGED; ARTICLE; BLOOD; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA MODIFICATION; FEMALE; GENETIC TRANSCRIPTION; HUMAN; LEUKOCYTE; LUNG SMALL CELL CANCER; MALE; METHYLATION; PREDICTION; PRIORITY JOURNAL; PYROSEQUENCING; SMOKING; ADULT; CARCINOMA, SMALL CELL; GENETICS; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; STATISTICAL MODEL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SMALL CELL; CPG ISLANDS; DNA METHYLATION; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; LEUKOCYTES; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 77953138943     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181d6e0b3     Document Type: Article

References (34)

1. Stupp R, Monnerate C, Turrisi AT. Small cell lung cancer: state of the art and future perspectives. Lung Cancer 2004;45:105-117.
2. Brownson RC, Chang JC, Davis JR. Gender and histologic type variations in smoking-related risk of lung cancer. Epidemiology 1992;3:61-64.
3. de Andrade M, Ebbert JO, Wampfler JA, et al. Environmental tobacco smoke exposure in women with lung cancer. Lung Cancer. 2004;43:127-134.
4. Jiang YH, Bressler J, Beaud et al. Epigenetics and human disease. Ann Rev Genomics Human Genet 2004;5:479-510.
5. Bjornsson HT, Fallin MD, Feinberg AP. An integrated epigenetic and genetic approach to common human disease. Trends Genet 2004;20:350-358.
6. Feinberg AP. Epigenetics at the epicenter of modern medicine. J Natl Cancer Inst 2008;299:1345-1350.
7. Dolinoy DC, Jirtle RL. Environmental epigenomics in human health and disease. Environ Mol Mutagen 2008;49:4-8.
8. Reik W. Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 2007;447:425-432.
9. Hsiung DT, Marsit CJ, Houseman EA, et al. Global DNA methylation level in whole blood as a biomarker in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2007;16:108-114.
10. Moore LE, Pfeiffer RM, Poscablo C, et al. Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study. Lancet Oncol 2008;9:359-366.
11. Widschwendter M, Apostolidou S, Raum E, et al. Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. PLoS One. 2008;3: e2656.
12. Yang P, Sun Z, Krowka MJ, et al. Alpha-1 antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. Arch Int Med 2008;168:1097-1103.
13. Yang P, Allen MS, Aubry MC, et al. Clinical features of 5, 628 primary lung cancer patients: experience at Mayo Clinic from 1997-2003. Chest 2005;128:452-462.
14. 1-antitrypsin deficiency allele carriers in lung cancer patients. Cancer Epidemiol Biomarkers Prev 1999;8:461-465.
15. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003;100:9440-9445.
16. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-577.
17. Tost J, Gut IG. Analysis of gene-specific DNA methylation patterns by pyrosequencing technology. Methods Mol Biol 2007;373:89-102.
18. Tost J, Gut IG. DNA methylation analysis by pyrosequencing. Nat Protoc. 2007;2:2265-2275.
19. Zeni E, Mazzetti L, Miotto D, et al. Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer. Eur Respir J 2007;4:627-632.
20. Wang H, Zhang Z, Li R, et al. Overexpression of S100A2 protein as a prognostic marker for patients with stage I non small cell lung cancer. Int J Cancer 2008;116:285-290.
21. Bartling B, Rehbein G, Schmitt WD, et al. S100A2-S100P expression profile and diagnosis of non-small cell lung carcinoma: impairment by advanced tumour stages and neoadjuvant chemotherapy. Eur J Cancer 2007;43:1935-1943.
22. Ota S, Ishii G, Goto K, et al. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced nonsmall-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer 2009;64:98-104.
23. Okuda K, Sasaki H, Dumontet C, et al. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. Lung Cancer 2008;62:105-112.
24. Cui H, Cruz-Correa M, Giardiello M, et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 2003;299:1753-1755.
25. Kohda M, Hoshiya H, Katoh M, et al. Frequent loss of imprinting of IGF2 and MEST in lung adenocarcinoma. Mol Carcinog 2001;31:184-191.
26. Kondo H, Suzuki H, Ueda R, et al. Frequent loss of imprinting of the h19 gene is often associated with its overexpression in human lung cancers. Oncogene 1995;10:1193-1198.
27. Scott RH, Douglass J, Baskcomb, et al. Constitutional 11p15 abnormalities, including heritable imprinting center mutations, cause nonsyndromic Wilms tumor. Nat Genet 2008;40:1329-1334.
28. Chalitchagorn K, Shuangshoti S, Hourpai N, et al. Distinctive pattern of LINE-1 methylation level in normal tissues and the association with carcinogenesis. Oncogene 2004;23:8841-8846.
29. Daskalos A, Nikolaidis G, Xinarianos G, et al. Hypomethylation of retrotransposable elements correlates with genomic instability in nonsmall cell lung cancer. Int J Cancer 2009;124:81-87.
30. Ogino S, Nosho K, Kirkner GJ, et al. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst 2008;100:1734-1738.
31. Suzuki M, Shigematsu H, Shames DS, et al. DNA methylation-associated inactivation of TGF-beta-related genes DRM/Gremlin, RUNX3, and HPP1 in human cancers. Br J Cancer 2005;93:1029-1037.
32. Sato K, Tomizawa Y, Iijima H, et al. Epigenetic inactivation of the RUNX3 gene in lung cancer. Oncol Rep 2006;15:129-135.
33. Li QL, Kim HR, Kim WJ, et al. Transcriptional silencing of the RUNX3 gene by CpG hypermethylation is associated with lung cancer. Biochem Biophys Res Commun 2004;314:223-228.
34. Yanada M, Yaoi T, Shimada J, et al. Frequent hemizygous deletion at 1p36 and hypermethylation downregulate RUNX3 expression in human lung cancer cell lines. Oncol Rep 2005;14:817-822.